Effects of Ranibizumab in Patients with Subfoveal Choroidal Neovascularization Attributable to Age-related Macular Degeneration
- 31 May 2009
- journal article
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 147 (5) , 831-837
- https://doi.org/10.1016/j.ajo.2008.12.005
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Randomized, Double-Masked, Sham-Controlled Trial of Ranibizumab for Neovascular Age-related Macular Degeneration: PIER Study Year 1American Journal of Ophthalmology, 2008
- Ranibizumab versus Verteporfin for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2006
- Ranibizumab for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2006
- Age-Related Macular Degeneration Is the Leading Cause of Blindness . . .JAMA, 2004
- Causes and Prevalence of Visual Impairment Among Adults in the UnitedStatesArchives of Ophthalmology (1950), 2004
- Placental Growth Factor, a Member of the VEGF Family, Contributes to the Development of Choroidal NeovascularizationInvestigative Opthalmology & Visual Science, 2003
- Vascular Endothelial Growth Factor Family and Receptor Expression in Human Choroidal Neovascular MembranesMicrovascular Research, 2002
- GUIDELINES FOR USING VERTEPORFIN (VISUDYNE®) IN PHOTODYNAMIC THERAPY TO TREAT CHOROIDAL NEOVASCULARIZATION DUE TO AGE-RELATED MACULAR DEGENERATION AND OTHER CAUSESRetina, 2002
- Photodynamic Therapy of Subfoveal Choroidal Neovascularization in Age-related Macular Degeneration With VerteporfinArchives of Ophthalmology (1950), 1999
- Basic Fibroblast Growth Factor and Vascular Endothelial Growth Factor Are Present in Epiretinal and Choroidal Neovascular MembranesAmerican Journal of Ophthalmology, 1996